Tekla Life Sciences Investors HQL | NYSE

Dividends

Company Overview:

Market Cap: $555.86M
Trailing PE: —
FWD PE: —
Payout Ratio (TTM): 26.8%
52-Week Range: $15.66 - $22.67

10 Year HQL Performance Metrics:

Total Return (with DRIP): 133.6% (8.86% CAGR)
Total Return (no DRIP): 75.7% (5.80% CAGR)
Share Price: -4.3% (-0.44% CAGR)
Yield on Cost (with DRIP): 32.17%
Total Invested: $10,000
Total Value (with DRIP): $23,360
Total Return $ (with DRIP): $13,360
Dividend Increase: 40.0% (3.51% CAGR)
Dividend Yield (FWD): 13.77% ($2.48)
HQL 10-yr Total Return ($10K invested)
1M 3M 6M YTD 1Y 3Y 5Y 10Y
HQL Share Price
1M 3M 6M YTD 1Y 3Y 5Y 10Y All
HQL Price CAGR:1Y: 4.95%2Y: 14.57%5Y: -2.65%10Y: -0.44%
HQL Dividend Charts
HQL - Dividends
HQL Dividend CAGR:1Y: 11.94%2Y: 6.90%5Y: 5.64%10Y: 3.36%
HQL - Dividend Payout Ratio
HQL Dividend Payout Ratio CAGR:1Y: -25.95%2Y: 0.00%5Y: 0.00%10Y: 9.66%
HQL - Dividend to Free Cash Flow Ratio
HQL Dividend to FCF Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Build Custom Charts
HQL - Chart 1
HQL - Chart 2
HQL - Chart 3

HQL Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

Revenue
HQL Revenue CAGR:1Y: 2,227.56%2Y: 605.92%5Y: 748.97%10Y: 238.41%
Earnings Per Share (EPS)
HQL EPS CAGR:1Y: 16.85%2Y: 83.29%5Y: 27.42%10Y: -0.93%
Net Income
HQL Net Income CAGR:1Y: 30.01%2Y: 96.62%5Y: 433.67%10Y: 106.87%
EBITDA
HQL EBITDA CAGR:1Y: -35.41%2Y: 0.00%5Y: 432.04%10Y: 106.33%
Free Cash Flow
HQL Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Free Cash Flow / Share
HQL Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Operating Income
HQL Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Gross Profit
HQL Gross Profit CAGR:1Y: 2,076.65%2Y: 582.65%5Y: 737.66%10Y: 236.15%
Shares Outstanding
HQL Shares Outstanding CAGR:1Y: 11.18%2Y: 7.71%5Y: 319.19%10Y: 108.78%
Share Buybacks
HQL Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Stock-Based Comp
HQL Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Expenses
HQL Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Revenue vs Net Income
EPS vs FCF / Share
EPS vs PE Ratio
FCF vs FCF / Share
FCF vs Stock Based Comp
Cash & Debt

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

REVENUE: Actual + Estimates
HQL Actual Revenue CAGR:1Y: 2,227.56%2Y: 605.92%5Y: 748.97%10Y: 238.41%
EPS: Actual + Estimates
HQL Actual EPS CAGR:1Y: 16.85%2Y: 83.29%5Y: 27.42%10Y: -0.93%
NET INCOME: Actual + Estimates
HQL Actual Net Income CAGR:1Y: 30.01%2Y: 96.62%5Y: 433.67%10Y: 106.87%
EBITDA: Actual + Estimates
HQL Actual EBITDA CAGR:1Y: -35.41%2Y: 0.00%5Y: 432.04%10Y: 106.33%

Ratios, Profit Margins & Return on Capital:

Net Profit Margin
HQL Net Profit Margin CAGR:1Y: -94.41%2Y: -72.15%5Y: -37.14%10Y: -38.87%
Gross Profit Margin
HQL Gross Profit Margin CAGR:1Y: -6.48%2Y: -3.29%5Y: -1.33%10Y: -0.67%
Price to Earnings
HQL Price to Earnings CAGR:1Y: 3.15%2Y: -41.40%5Y: -22.53%10Y: -3.28%
Price To Sales Ratio
HQL Price To Sales Ratio CAGR:1Y: -94.23%2Y: -83.67%5Y: -51.30%10Y: -40.87%
Return on Capital Employed
HQL Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Return on Invested Capital
HQL Return on Invested Capital CAGR:1Y: 0.00%2Y: 6,092.22%5Y: 0.00%10Y: 304.12%

Compare stocks side-by-side

HQL Dividends Info:

Annual Dividend: $2.48
Forward Yield: 13.77%
Ex-Dividend Date: 2026-08-24
Lifetime Dividends / Share: $48.59

Projected Future Returns & Dividends for HQL

Based on past 10-year performance, here are HQL growth metrics:

Share price CAGR of -0.44%
Dividend CAGR of +3.51%

Using HQL CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

HQL (DRIP)HQL - No DRIP
Current Price$18.01$18.01
Start Shares555.25555.25
Start Value$10,000$10,000
  
After 10 years:
Final Share Count2,798.00555.25
Dividends Payment$0.88$0.88
Annual Dividends$9,799$1,945
Yield on cost97.99%19.45%
Share Price$17.23$17.23
Total Dividends$39,330$16,163
Final Value$48,223$25,732

Estimated Future Value + Dividends - HQL

NOTE: Above numbers are our estimate based on HQL's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Company Info

Tekla Life Sciences Investors (HQL) had its IPO on 1992-05-01, and is traded on NYSE stock exchange.

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.

HQL website: http://www.abrdnhql.com


Loading signals…

DCF Model — HQL

Value from:
Pay up to today
—
vs current price $18.01
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →